A FormBlends network publication
Choosing a GLP-1 Clinic

How to evaluate a clinic's pharmacy partner

The pharmacy matters as much as the prescriber when the product is compounded. What to ask a clinic about the pharmacy, how to verify its licence in your state, 503A vs 503B in one paragraph, what a certificate of analysis should show, and where the detailed guides live.

By FormBlends editorial teamUpdated September 4, 2026Educational, not medical advice

When the product is a brand pen from a retail pharmacy, the pharmacy is not a decision. When it is a compounded vial from a pharmacy the clinic chose, the pharmacy is half the decision, and the clinic has an interest in you not looking too closely. This page covers what to ask the clinic; the detailed verification guides live at formblendscompounding.com.

What to ask the clinic

  1. Which pharmacy will dispense my medication, and in which state is it located? A name and a state. If the clinic will not say until after you pay, that is the answer. The FDA's March 3, 2026 warning letters specifically addressed programs advertising compounded products under their own brand as if they were the manufacturer.
  2. Is it a 503A pharmacy or a 503B outsourcing facility? The FDA's compounding page explains the two. In one paragraph: 503A pharmacies compound for individual prescriptions under state board oversight; 503B facilities register with the FDA, are FDA-inspected and follow manufacturing-grade quality rules. Neither makes an approved drug. The 503A vs 503B explainer goes deeper.
  3. Is the pharmacy licensed to ship into my state? Most states require a non-resident pharmacy licence. Verify it yourself (below).
  4. Can I see a certificate of analysis for my batch? A COA shows what an independent or in-house lab found in the batch: identity, potency, sterility, endotoxin. How to read a COA explains each line and what a good one looks like.
  5. What form is the active ingredient? The FDA has raised concerns about salt forms (semaglutide sodium, semaglutide acetate) that are not the same substance as the approved drug. Salt forms and research-use-only wording covers it.
  6. On what basis is the pharmacy compounding this now? The shortages that permitted large-scale compounding of these drugs were resolved in 2024 and 2025; what a compounder may still do is described at what compounders may do now. A clinic should be able to explain the basis without evasion.
  7. Who do I contact about a product problem, the clinic or the pharmacy? You want both answers.

Verify the pharmacy yourself

Ten minutes, two lookups:

The pharmacy vetting checklist generates a printable list from what you already know about the offer.

What the clinic's answers tell you about the clinic

A clinic that names its pharmacy, states the 503A/503B status, provides a COA on request and explains the legal basis is treating the pharmacy as a partner it is accountable for. A clinic that treats the question as a nuisance is telling you it has not looked either. Since the clinic chose the pharmacy and profits from the arrangement, its diligence is the only diligence between the pharmacy and you, apart from your own.

When the pharmacy is fine and the clinic is not

The reverse also happens: a well-run 503B facility supplying a clinic whose intake is a form and whose follow-up is a reorder button. A good pharmacy does not fix a thin clinic. Use what a good intake includes and how follow-up should work for that half of the evaluation.

Questions people ask

Does it matter whether the pharmacy is 503A or 503B?

It changes who inspects it and what it may do. A 503A pharmacy compounds for individual prescriptions under state board oversight; a 503B outsourcing facility registers with the FDA, is inspected by the FDA and follows current good manufacturing practice. Neither produces an FDA-approved drug. formblendscompounding.com explains the difference and what each may do now that the shortages have been resolved.

The clinic says the pharmacy is 'FDA registered'. Is that the same as approved?

No. Registration is a listing; approval is a review of a specific drug's safety and effectiveness. A 503B facility is registered with the FDA. Its products are still not FDA approved. A clinic that blurs the two is doing exactly what the FDA's March 2026 warning letters addressed.

Sources

  1. FDA: Human Drug Compounding (503A and 503B; compounded drugs are not FDA approved) Accessed September 4, 2026.
  2. FDA: Registered outsourcing facilities (503B) Accessed September 4, 2026.
  3. NABP: state boards of pharmacy directory Accessed September 4, 2026.
  4. FDA press release, March 3, 2026: FDA warns 30 telehealth companies against illegal marketing of compounded GLP-1s Accessed September 4, 2026.
  5. FDA: FDA's concerns with unapproved GLP-1 drugs used for weight loss Accessed September 4, 2026.

Canonical URL: https://formblendsclinics.com/safety/evaluating-a-clinics-pharmacy-partner. Written by the FormBlends editorial team. This page is educational and is not medical advice; see the medical disclaimer.